SCM
NGEN

Stonepine Capital Management’s NervGen Pharma NGEN Stock Holding History

Stonepine Capital Management’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$560K Buy
+271,678
New +$843K 0.32% 61

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Stonepine Capital Management's NGEN Position: Q2 2026 in Review

Stonepine Capital Management opened a new position in NervGen Pharma (NGEN) in Q2 2026: 271,678 shares worth $560K. The stake represents 0.32% of the portfolio and ranks #61 among its holdings.

62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Stonepine Capital Management held 271,678 shares of NervGen Pharma worth $560K as of Q2 2026.
  • NervGen Pharma was a new Stonepine Capital Management position in Q2 2026.
  • NervGen Pharma made up 0.32% of Stonepine Capital Management's portfolio in Q2 2026, its #61 holding.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.